A database of FDA approved therapeutic peptides and proteins
Details of Th1211 which contains 1 entries. |
| Entry 1 | |
| (1) Primary information | |
|---|---|
| ID | 1820 |
| ThPP ID | Th1211 |
| Therapeutic Peptide/Protein Name | Ixekizumab |
| Sequence | NA view full sequnce in fasta |
| Functional Classification | Ic |
| Molecular Weight | 1,46,158 |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting Point (℃) | NA |
| Half Life | The mean (geometric CV%) half-life was 13 days |
| Description | Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) with neutralizing activity against IL-17A. Ixekizumab is produced by recombinant DNA technology in a recombinant mammalian cell line and purified using standard technology for bioprocessing. Ixekizumab is comprised of two identical light chain polypeptides of 219 amino acids each and two identical heavy chain polypeptides of 445 amino acids each, and has a molecular weight of 146,158 Daltons for the protein backbone of the molecule. |
| Indication/Disease | For the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy |
| Pharmacodynamics | No formal pharmacodynamic studies have been conducted with TALTZ. |
| Mechanism of Action | Ixekizumab is a humanized IgG4 monoclonal antibody that selectively binds with the interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Ixekizumab inhibits the release of proinflammatory cytokines and chemokines. |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | Ixekizumab reached peak mean (±SD) serum concentrations (Cmax) of 16.2 ±6.6 mcg/mL by approximately 4 days post dose. |
| Volume of Distribution | volume of distribution at steady-state was 7.11 L |
| Clearance | The mean systemic clearance was 0.39 L/day |
| Categories | NA |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | NA |
| Information of corresponding available drug in the market | |
| Brand Name | Taltz |
| Company | Eli lilly |
| Brand Discription | TALTZ injection is a sterile, preservative free, clear and colorless to slightly yellow solution, for subcutaneous use available as 80 mg of ixekizumab in a 1 mL single-dose prefilled autoinjector or a single-dose prefilled syringe. The prefilled autoinjector and prefilled syringe each contain a 1 mL glass syringe with a fixed 27 gauge ½ inch needle. The TALTZ 80 mg prefilled autoinjector and prefilled syringe are manufactured to deliver 80 mg of ixekizumab. |
| Prescribed for | Taltz is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. |
| Chemical Name | NA |
| Formulation | 80 mg of ixekizumab in a 1 mL single-dose prefilled autoinjector or a single-dose prefilled syringe |
| Physcial Appearance | Sterile, preservative free, clear and colorless to slightly yellow solution |
| Route of Administration | Subcutaneous |
| Recommended Dosage | TALTZ is administered by subcutaneous injection. The recommended dose is 160 mg (two 80 mg injections) at Week 0, followed by 80 mg at Weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks. |
| Contraindication | TALTZ is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients |
| Side Effects | Infections; Hypersensitivity Reactions; Inflammatory Bowel Disease |
| Useful Link | http://www.rxlist.com/taltz-drug.htm; http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003943/WC500205806.pdf |
| PubMed ID | 27313431, 26651519, 25484055, 24284914, 23254906, 28042711, 28026823, 27836567, 27826996 |
| 3-D Structure | N.A. |